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Summary.-The effect of 6 putative prognostic factors on survival was studied in
patients with Stages III and IV malignant teratoma of the testis. Differences between
survival curves were tested for statistical significance. A diameter > 5 cm in the larg -
est tumour mass, and >8 pulmonary metastases were adverse prognostic factors
(P=00004 and 0f008 respectively). Patients with malignant teratoma, trophoblastic,
fared worse than those with malignant teratoma, undifferentiated, and malignant
teratoma, intermediate (P=00011 and 0-023 respectively). Previous chemotherapy or
radiotherapy had no significant effect.
Serum o-foetoprotein (AFP) above 103 MRC u/ml and serum : subunit of human
chorionic gonadotrophin (hCG) above 105 miu/ml, were found to predict a poor prog-
nosis (P =0-010 and 0-001 respectively). A combination of measurements of the tumour
markers gave the most consistent indication of prognosis, in that patients with either
AFP > 103 MRC u/ml or hCG > 105 miu/ml, or both, fared much worse than those
with neither factor (P=0.001).
Serum concentrations of AFP and hCG should be stated in reports of treatment of
testicular teratoma in order to provide a basis for comparison with other series.
Regular and frequent measurements of these markers are appropriate throughout
the clinical management of patients with malignant teratoma.
SINCE THE INTRODUCTION of combina-
tion chemotherapy for advanced meta-
static testicular teratoma in the 1 960s,
there has been a progressive improvement
in the long-term disease-free survival
(MacKenzie, 1966; Jacobs et al., 1979).
Improved chemotherapy regimens includ-
ing vinblastine and bleomycin (Samuels
et al., 1976) and, more recently, cis-
platinum (Golbey et al., 1979; Einhorn &
Donohue, 1979; Newlands et al., 1980)
have produced disease-free survival of
more than 2 years in 30-74°O of patients.
It would be advantageous to be able to
predict which patients are unlikely to
achieve full remission with present therapy.
The relationship of tumour bulk to
prognosis is widely recognized (Samuels
et al., 1976; Einhorn & Donohue, 1977;
Peckham et al., 1977) but tumour bulk, as
estimated by a variety of methods, is not
readily quantified. Studies of putative
prognostic factors related to tumour bulk
are reported in this paper.
Human chorionic gonadotrophin (hCG)
and a-foetoprotein (AFP) are found separ-
ately or together in the serum of more
than 75% of patients with disseminated
malignant teratoma (Newlands et al.,
1976; Javadpour, 1979). Changes in the
concentration of these markers in serum
are usually related to the bulk of tumour
in an individual patient (Javadpour,
1979). The proportion of patients with
hCG or AFP detectable in the serum is
higher in metastatic than in localized
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disease (Schultz et al., 1978). Although not
all cells in malignant teratomas secrete
these markers, it is possible that their
serum concentrations can be related to
overall tumour bulk and, on the evidence
presented here, can provide the most con-
sistent indication of prognosis.
METHODS
Forty-seven patients with malignant terat-
oma of the testis Stages III (5) and IV (42)
(Smithers & Wallace, 1962) began treatment
between August 1975 and March 1979. Ages
were 16-45 years (mean and median 27). The
criteria of Pugh & Cameron (1976) wvere used
for histological classification.
The largest tumour diameter was deter-
mined by clinical measurement, plain radio-
graphy of the chest, bipedal lymphangio-
graphy or computerized tomography of the
chest or abdomen. Assays for the : subunit of
hCG used the method of Kardana & Bag-
shaw%Ne (1976) and for AFP the method of
Seppakl & Ruoslahti (1972) automated as
described by BagshawTe (1975).
All patients received cytotoxic chemo-
therapy, surgery and radiotherapy being used
where appropriate. From August 1975 to
April 1977, multiple cytotoxic drug regimens
were being developed, based on combinations
of vincristine, methotrexate w-ith folinic acid
rescue, cyclophosphamide, bleomycin, actino-
mycin D and adriamycin. From April 1977 a
regimen comprising vincristine, methotrexate,
bleomycin and high-dose cis-platinum was
given for the 2 courses, followed by courses
of VP 16-213, actinomycin D and cyclo-
phosphamide alternating wvith hydroxyurea,
vinblastine and chlorambucil, and vincristine,
methotrexate and bleomycin (for details see
Neuwlands et al., 1980). The rate of accrual of
patients in various prognostic groups was
approximately constant throughout the study.
Life tables w%ere constructed using the
Statistical Package for the Social Sciences
Program for Survival Analysis, Version 7.0
(Nie et al., 1977) in which differences in the
survival curves were tested for statistical
significance by a non-parametric technique
described by Lee & Desu (1972). Data were
processed by these programs at the
University of London Computer Centre, via
the Charing Cross Hospital Medical School
Computer Uniit.
RESULTS
Forty-seven consecutive patients start-
ing treatment between August 1975 and
March 1979 were investigated for survival
up to June 1980. The 6 putative prog-
nostic factors studied at the start of
chemotherapy were: (1) largest tumour
mass at any site > 5 cm diameter; (2)
more than 8 lung metastases; (3) previous
chemotherapy or radiotherapy; (4) histo-
logical type; (5) serum concentration of
AFP and (6) serum concentration of
hCG. An adverse prognostic factor is
defined for this purpose as an indicator,
determined at the start of therapy, and
associated with a low probability of sur-
vival. This was determined by finding a
statistically significant difference between
survival curves for groups of patients with
or without the indicator.
Tutmour bulk and number of pulmonary
metasta8ses
Figs 1 and 2 show that a diameter
> 5 cm in a tumour mass at any site, or
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FIG. 1. Life tables for groups with largest
tumour mass with a diameter above (19
patients) (M dead, O alive) or below 5 cm
(28 patients) (0 dead, O alive). P=0 004.
85S1
J. R. GERMA-LLUCH, R. H. J. BEGENT AND K. D. BAGSHAWE
1.0
0.9
0.8
0.7
- 11;
5 surviving >40 months
2 surviving, 40 months
c
°= 0. 5
0o
C._
E; 0.4
0.3 1
0.2
0.1
10 20
Mlonths
30 40
FIe. 2. Life tables for groups with pulmonary
metastases numbering 8 or less (31 patients)
(0 dead, 0 alive) or more than 8 (16
patients) (* dead, L1 alive) on a plain radio-
graph. P= 0-008.
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FIe. 3.-Life tables for groups with (19
patients) (0 dead, 0 alive) or without
previous chemotherapy or radiotherapy (28
patients) (* dead, O alive). P= 0079.
the presence of > 8 lung metastases, were
adverse prognostic factors (X2 = 8 08, d.f.
=1, P=0-004 and x2=7l14, P=0-008
respectively).
Previous treatment
Patients who had received previous
chemotherapy or radiotherapy fared bet-
ter than those without previous treat-
ment, but the difference did not reach
statistical significance (X2 = 3 08,P= 0 079)
(Fig. 3). It was found that 76% of pre-
viously untreated patients had one or
more of the 4 adverse prognostic factors
related to tumour bulk, compared with
only 48% in the previously treated group.
Histological type
Patients with malignant teratoma, tro-
phoblastic, fared significantly worse than
the other two groups (Fig. 4); X2 = 6 45,
P = 0 011 for the comparison with malig-
nant teratoma, undifferentiated, and x2
= 5-16, P= 0*023 for the comparison with
malignant teratoma, intermediate.
AFP
Fig. 5 shows that AFP > 103 MRC u/ml
(1 MRC u/ml =1 ,ug/l) immediately before
starting chemotherapy, is associated with
a relatively poor prognosis (x2= 6X67,
P= 0.010). AFP > 5 x 102 MRC u/ml had
no significant effect on survival (x2 =
1 165, P = 0 200) when investigated by the
same method (data not shown).
hCG
Fig. 6 shows that hCG > 105 miu/ml is
associated with a poor prognosis (x2 =
12X18, P=0.001). A significant but less
marked difference was also found between
hCG above and below 5 x 104 miu/ml
(X2= 689,P=0009; data not shown).
Tumour markers in combination
The most consistent indication of prog-
nosis was given by combination of meas-
urements of both tumour markers: patients
with neither AFP > 103 MRC u/ml, nor
hCG > 105 miu/ml, fared significantly
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FIG. 4.-Life tables for groups with tumours
in the 3 histological categories: MTU=
malignant teratoma undifferentiated (15
patients) (squares); MTI = malignant terat-
oma intermediate (24 patients) (circles);
MTT = malignant teratoma trophoblastic
(8 patients) (triangles). Open symbols,
alive; closed symbols, dead.
better than those with either or both
factors (X2 = 17-79, P = 0O001; Fig. 7).
DISCUSSION
The results show that serum concentra-
tions of AFP > 103 MRC u/ml and hCG
> 105 miu/ml predict poor survival in
patients with malignant teratoma of the
testis. A large bulk of tumour at the start
of treatment also predicts poor prognosis,
but high concentrations of the tumour
markers appear to give a more accurate
indication of the outcome, producing the
highest x2 (17.79) when used in combina-
tion. This may be because they reflect the
number of tumour cells more accurately
than the relatively crude methods for
physical assessment of tumour bulk which
cannot assess the viable tumour fraction
within a mass.
Whilst hCG and AFP are produced by
trophoblastic and yolk-sac elements of the
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FIG. 5.-Life tables for groups with serum
AFP above (8 patients) (squares) and below
103 MRC u/mI (39 patients) (circles). P=
0-01.
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FIG. 6. Life tables for groups of patients
with serum hCG above (8 patients) (squares)
and below 105 miu/ml (39 patients) (circles).
P = 0-001.
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1.0 ^shows that by making use of both AFP
and hCG it is possible to define a poor
0.9 > prognosis group, even in patients receiving
cis-platinum therapy.
0.8
. New approaches to therapy beyond
0.7 \5 surviving>40 months those recently reported (Samuels et al.,
.=> i 1976; Golbey et al., 1979; Einhorn &
Donohue, 1979; Newlands et al., 1980)
should be applied to this poor-prognosis
& 0.5 1, group. This may for example involve the
use of extra courses of cis-platinum as
*-,>0.4 > suggested by Einhorn & Donohue (1979)E h and Storer et al. (1979) for patients with a
0.3 large bulk of tumour or high levels of
tumour markers at the beginning of
0.2 therapy.
2 surviving>40 months Interpretation of the relative merits of
0.1 various treatment regimens for advanced
malignant teratoma is currently handi-
10 20 30 40 capped by difficulties in determining the
Months prognostic factors applying to different
FiG. 7.-Life tables for groups of patients groups of patients. Physical measurement
with neither serum AFP above 103 MRC of tumour bulk is of considerable help, but
u/ml nor serum hCG above 105 miu/ml (33 differences in measurements by individual
patients) (circles) and those with one or both observers using various diagnostic toolsof these factors (14 patients) (squares).P= 0-001. mean that comparisons between centres
are often invalid. Assays for hCG and
tumour respectively, it is important to AFP using internationally accepted stan-
recognize that testicular teratomas fre- dards have the potential to overcome this
quently contain elements which do not problem, and it is suggested that serum
produce these markers (Kuram etal., 1977). hCG and AFP data for each patient at the
However, in our experience, patients with start of treatment should be stated in
a large bulk of tumour almost always have reports of therapeutic trials in malignant
circulating AFP and hCG. For example, teratoma.
the largest tumour mass was < 5 cm in The recognition of the grave prognostic
diameter and there were < 8 lung meta- significance of high levels of hCG and AFP
stases in 6/7 non-marker-producing pa- is likely to be of most benefit to patients
tients in this series. The tumour appears with testicular teratoma if assays are
to have been eradicated in all these done regularly from the earliest suspicion
patients, and the good prognosis associa- of the diagnosis, as recommended by the
ted with the absence of detectable circu- International Research Group for Car-
lating AFP and hCG may be explained by cinoembryonic Proteins (N0rgaard-Peder-
the small bulk of tumour. Alternatively son et al., 1978). In our view, measure-
they may contain a group of tumours ments should also be made monthly for
with a different natural history. at least 5 years after the patients are
A number of authors have suggested apparently free from disease by all para-
that high concentrations of tumour mar- meters. In this way it will usually be pos-
kers might be associated with poor prog- sible to detect early relapse and re-start
nosis (Einhorn & Donohue, 1977; Storer appropriate treatment at a stage when
et al., 1979; Golbey et al., 1979). Our current methods of therapy already give a
evidence supports this contention, and good prognosis.
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